Cagent Vascular
Cagent Vascular is a Wayne, Pennsylvania-based private medical device company that develops and sells the Serranator PTA Serration Balloon Catheter, the first FDA-cleared and CE-marked serrated balloon catheter, used by interventional cardiologists and vascular surgeons to treat peripheral artery disease across above-the-knee, below-the-knee, and below-the-ankle vessels.
- Company typePrivate
- Founded2014
- HeadquartersWayne, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cagent Vascular does
Cagent Vascular is a privately held, venture-backed medical device company headquartered in Wayne, Pennsylvania, that develops and commercializes the Serranator® PTA Serration Balloon Catheter, the first and only FDA-cleared and CE-marked serrated balloon catheter for endovascular treatment of peripheral artery disease (PAD). The company's proprietary Serration Remodeling Therapy (SRT) embeds stainless-steel serrated strips on a standard angioplasty balloon, applying concentrated point force at low inflation pressures to score along the internal elastic lamina. The stated clinical benefits versus plain balloon angioplasty are predictable lumen gain, reduced recoil, fewer dissections, and lower bailout stent rates across lesion morphologies including above-the-knee (ATK), below-the-knee (BTK), below-the-ankle (pedal), arteriovenous fistula, and iliac applications.
Cagent's product architecture is a single-platform-plus-variants model: the core Serranator catheter (2.5–8.0 mm diameters, 40–120 mm lengths, 0.014"/0.018" guidewire compatible), the Serranator SL-PRO variant for chronic limb-threatening ischemia (CLTI) and pedal disease, and the next-generation Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon remodeling in a disposable catheter. The company has built a portfolio of prospective, core-lab adjudicated clinical studies (PRELUDE, PRELUDE-BTK, Recoil, Pedal, Serranator vs POBA OCT, plus the global REMODEL II pivotal trial for SONIC) and a peer-reviewed publication record, particularly in below-the-ankle interventions. Intellectual property comprises 16 issued US patents and pending foreign applications covering the catheter and method-of-use.
The business model is direct sale of disposable catheters to hospitals, ambulatory surgery centers, and office-based labs through a US field sales force of Sales Territory Managers and Clinical Specialists, with international distribution in the EU and MENA via a partnership with 3comma Medical. Pricing is quote-based and not publicly disclosed. Ancillary revenue support comes from physician education, reimbursement guides, and clinical programs such as the POINT FORCE Observational Registry, which underpin device utilization but are not direct revenue streams. The company has raised approximately $107 million across multiple rounds (2021 exempt offering, 2024 Series C, 2025 growth debt, 2026 Series D), with USVP as the dominant institutional shareholder across all equity rounds. Customers are healthcare providers — primarily interventional cardiologists, vascular surgeons, and endovascular specialists — and named clinical reference sites include Hartford HealthCare, Prisma Health, Baylor Scott & White Health, UT Southwestern, Christiana Care, Clara Maass Medical Center, Columbia University Medical Center, and a vascular centre in Arnsberg, Germany.
Cagent Vascular firmographics
Firmographics- Name
- Cagent Vascular
- Legal name
- Cagent Vascular, Inc.
- Website
- https://cagentvascular.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cagent Vascular is a Wayne, Pennsylvania-based private medical device company that develops and sells the Serranator PTA Serration Balloon Catheter, the first FDA-cleared and CE-marked serrated balloon catheter, used by interventional cardiologists and vascular surgeons to treat peripheral artery disease across above-the-knee, below-the-knee, and below-the-ankle vessels.
- Ownership category
- akta.pro rank
Cagent Vascular industry classification
Industry- Product category
- Peripheral Vascular Intervention Devices
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
- akta.pro secondary industries
- Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK), Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)
Keywords
Where Cagent Vascular is headquartered
LocationHeadquarters
- HQ city
- Wayne
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cagent Vascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Capital Equipment Sales (Serranator PTA Serration Balloon Catheter): Revenue is generated primarily through one-time sale of the Serranator balloon catheter to hospitals, ambulatory surgery centers, and office-based labs. SKUs cover diameters 2.5–8.0 mm and lengths 40–120 mm with GTINs listed in the product ordering table. Sales motion is supported by Sales Territory Managers and Clinical Specialists.
- Reimbursement Support & Clinical Education (Ancillary): Cagent publishes reimbursement guides and Instructions for Use (IFU) and runs physician education programs (webinars, case studies, Serranator POINT FORCE Observational Registry) to support adoption and continued usage of its disposable catheter; not a direct revenue stream but underpins device utilization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing; not publicly disclosed |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels11 records
Cagent Vascular product offering
Product offeringCore offering
Cagent Vascular develops and sells the Serranator PTA Serration Balloon Catheter, a single-use percutaneous transluminal angioplasty catheter with embedded stainless-steel serrated strips that deliver concentrated point force to remodel the arterial wall at low inflation pressures. The catheter is sold in multiple diameters (2.5–8.0 mm) and lengths for above-the-knee, below-the-knee, below-the-ankle, and arteriovenous fistula interventions in patients with peripheral artery disease. The platform is being extended with the Serranator SL-PRO variant for CLTI and pedal disease, and the Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon-based remodeling.
Product overview
Cagent Vascular's offering is a single-product-platform-plus-variants architecture built around its proprietary Serration Remodeling Therapy (SRT) technology. The core product is the Serranator PTA Serration Balloon Catheter, a serrated angioplasty balloon for treating peripheral artery disease; the SL-PRO is a specialized variant for CLTI and pedal disease, and the Serranator SONIC IVL System is a next-generation device that combines intravascular lithotripsy with the Serranator serrated balloon. Together these named products, the SRT technology platform, and a clinical/education program (registries, studies, case libraries, webinars) form an integrated peripheral-vascular intervention franchise marketed in the U.S. and Europe.
Differentiator
Problem solved
Functional benefit
Brands
- Serranator: Serranator PTA Serration Balloon Catheter — Cagent Vascular's flagship commercial product line for vessel preparation using Serration Remodeling Therapy (SRT) to treat peripheral artery disease (above-the-knee, below-the-knee, and fistulas).
- Serranator SL-PRO
Products and services
- Serranator PTA Serration Balloon Catheter Flagship single-use percutaneous transluminal angioplasty (PTA) balloon catheter featuring embedded stainless-steel serrated strips that deliver concentrated point force along the arterial wall. Available in 2.5–8.0 mm diameters and 40–120 mm lengths, 0.014" and 0.018" guidewire compatible, 6F/7F sheath compatible, 110–150 cm catheter lengths, for above-the-knee, below-the-knee, below-the-ankle, and fistula interventions in patients with peripheral artery disease.
- Serranator SL-PRO Variant of the Serranator PTA Serration Balloon Catheter specifically indicated for chronic limb-threatening ischemia (CLTI) and pedal (below-the-ankle) disease, extending the Serration Remodeling Therapy platform to smaller-vessel, infrapopliteal applications.
- Serranator SONIC Intravascular Lithotripsy (IVL) System Next-generation disposable catheter that combines ultrasonic acoustic waves (intravascular lithotripsy) with the serrated balloon-based Serranator remodeling platform to treat complex calcified arterial disease; designed to support the global REMODEL II pivotal trial and a future coronary artery version.
Companies that use Cagent Vascular
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles1 record
Cagent Vascular technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cagent Vascular partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and flagship.
- Columbia University Medical CentercoreClinical research partner for the Serranator vs POBA OCT Study, with patient enrollment initiated April 10, 2025. Columbia University Medical Center generates core-lab adjudicated imaging and clinical evidence used to differentiate Serranator from plain balloon angioplasty.
- 3comma MedicalflagshipStrategic partnership announced April 3, 2025 to expand international distribution of the Serranator product family across the European Union (EU) and MENA regions. 3comma Medical acts as the regional distributor enabling Cagent Vascular's commercial reach outside the US.
- Serranator SL-PRO Investigator Sites (CLTI and Pedal Disease)coreInvestigator sites supporting the launch and clinical evaluation of the new Serranator SL-PRO product for critical limb ischemia (CLTI) and pedal disease, announced February 3, 2025.
- Serranator POINT FORCE Observational Registry InvestigatorscoreMulti-physician observational registry initiated January 28, 2025 to collect real-world clinical outcomes on the Serranator across multiple sites and operators, generating evidence to support adoption and reimbursement.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Cagent Vascular competitors and assessment
Company assessmentDirect peers
- Shockwave Medical: Shockwave Medical pioneered intravascular lithotripsy (IVL) for calcified arterial disease and was acquired by Johnson & Johnson for ~$13B. Cagent's Serranator SONIC IVL system directly competes with Shockwave's M5+ and C2+ IVL catheters in peripheral and emerging coronary indications, making it the most analogous peer.
- Surmodics: Surmodics focuses on peripheral drug-coated balloon technology, including the SurVeil DCB. It competes with Cagent for hospital accounts treating PAD and is a relevant direct peer in peripheral vascular intervention.
- AngioDynamics: AngioDynamics offers peripheral vascular products including the AngioVac system and specialty catheters. As a smaller public competitor focused on vascular interventions, it is comparable in scale and GTM motion to Cagent.
Broad incumbents
- Medtronic: Medtronic offers the IN.PACT Admiral drug-coated balloon and a broad peripheral vascular portfolio (including the recent Deep IVL acquisition). It is a key competitor for hospital formulary access and physician share in peripheral artery disease treatment.
- Abbott: Abbott's peripheral vascular portfolio includes Stellarex drug-coated balloons and the CSI orbital atherectomy system acquired in 2023. It competes directly with Cagent in vessel preparation and PAD lesion treatment across the same hospital and OBL channels.
- BD (Becton Dickinson): BD's peripheral intervention portfolio includes the Lutonix drug-coated balloon and atherectomy devices. It competes with Cagent for hospital and office-based lab accounts treating peripheral artery disease and is a broad incumbent in the peripheral vascular space.
- Philips: Philips Volcano and Philips IGT Devices offer peripheral IVUS, Phoenix atherectomy, and related vessel preparation tools. Its broad peripheral portfolio and installed-base imaging franchises make it a meaningful adjacent competitor in vessel preparation.
- Boston Scientific: Boston Scientific offers cutting and scoring balloon technology (Flextome, Wolverine) historically used in coronary and peripheral vessels, and a broader peripheral and coronary intervention portfolio. It is a relevant comparable for serration/scoring balloon mechanics and procedural adoption.
Emerging players
- Penumbra: Penumbra's Indigo peripheral thrombectomy system and broader vascular franchise position it as a peripheral interventional peer. While its primary focus is mechanical thrombectomy, it overlaps with Cagent in endovascular peripheral procedures.
- Inari Medical (Stryker): Inari Medical (acquired by Stryker in 2025) is a peripheral interventional specialist with FlowTriever and ClotTriever systems for venous thromboembolism. It is comparable as a high-growth, focused peripheral interventional company selling disposables into the same hospital and OBL call points.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Cagent Vascular social profiles
Digital presenceCagent Vascular compliance and trust
Trust signalCompliance3 records
Cagent Vascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cagent Vascular leadership team
Management profileNumber of profiles
Profiles8 records
Cagent Vascular funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cagent Vascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cagent Vascular
What does Cagent Vascular do?
Cagent Vascular develops and sells the Serranator PTA Serration Balloon Catheter, a single-use percutaneous transluminal angioplasty catheter with embedded stainless-steel serrated strips that deliver concentrated point force to remodel the arterial wall at low inflation pressures. The catheter is sold in multiple diameters (2.5–8.0 mm) and lengths for above-the-knee, below-the-knee, below-the-ankle, and arteriovenous fistula interventions in patients with peripheral artery disease. The platform is being extended with the Serranator SL-PRO variant for CLTI and pedal disease, and the Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon-based remodeling.
Is Cagent Vascular a public or private company?
Cagent Vascular is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cagent Vascular founded?
Cagent Vascular was founded in 2014. It employs 51 to 100 people.
Where is Cagent Vascular based?
Cagent Vascular is headquartered in Wayne, United States, in the North America region.
How does Cagent Vascular make money?
Two revenue lines are on record. Capital Equipment Sales (Serranator PTA Serration Balloon Catheter) is the primary driver. The others are reimbursement Support & Clinical Education (Ancillary).
Who are Cagent Vascular's main competitors?
Direct peers on record are Shockwave Medical, Surmodics and AngioDynamics. Broad incumbents are Medtronic, Abbott, BD (Becton Dickinson), Philips and Boston Scientific. Emerging players are Penumbra and Inari Medical (Stryker).
Does Cagent Vascular have an API?
No public API is recorded for Cagent Vascular.
What industry is Cagent Vascular in?
Cagent Vascular's product category is Peripheral Vascular Intervention Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy), with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its SIC code is 3842.